Cadence Raises $100M for Chronic Care AI
- •Cadence secured $100 million in series C funding led by Spark Capital to expand AI chronic care agents.
- •The platform currently serves over 100,000 patients across 20 health systems and tripled annual recurring revenue in 2025.
- •Clinical studies show a 27% reduction in hospital admissions and 70% improvement in blood pressure control for patients.
Health tech startup Cadence announced a $100 million series C funding round on June 23, 2026, aimed at scaling its AI agents designed for chronic disease management. Spark Capital led the investment, with additional participation from Thrive Capital, General Catalyst, Coatue, B Capital, Corewell Health Ventures, Memorial Hermann, and Duke Health. The company previously raised a $100 million series B round in December 2021 and intends to utilize this capital to advance its AI technologies, expand value-based care models, and enter additional health systems.
Cadence currently works with more than 20 health systems and supports over 100,000 active patients. Its Clinical Intelligence platform integrates directly into electronic medical records (EMRs) and clinical workflows to provide daily vital monitoring, medication adjustment support, and personalized lifestyle coaching. According to company executives, these supervised AI agents help address clinical labor constraints, with the platform tripling its annual recurring revenue in 2025 and saving Medicare approximately $2.7 million on a weekly basis.
The company also confirmed new strategic affiliations with Duke Health and Texas Health Resources. Peer-reviewed research highlights the effectiveness of the platform; for example, a Mayo Clinic study reported a 27% reduction in hospital admissions and a $1,302 per-patient annual decrease in total cost of care. Additionally, a study published in the Journal of the American College of Cardiology observed a 70% improvement in blood pressure control among hypertension patients enrolled in the company’s remote patient care program. Cadence Founder and CEO Chris Altcheck stated that the goal of the current investment is to build the necessary infrastructure to scale treatment to millions of patients.